- Q2-2018 ·
Frost & Sullivan Independent Equity Research
Cellect Biotechnology Ltd.: Company’s clinical development on track; we expect positive interim results in the coming months. Target Price unchanged.
Company: Cellect Biotechnology Ltd.
Report type: Quarterly Update
Published on: August 30th, 2017
Cellect research articles:
All articles loaded
No more articles to load